Viatris Clears US Symbicort Hurdle But Loses Key Patent Fight To AstraZeneca
Three US Patents Not Invalid Due To Obviousness; Appeal Planned
Executive Summary
Viatris and partner Kindeva Drug Delivery are celebrating a first tentative nod for a generic to one of the most significant respiratory opportunities in the US, but cannot launch at present with the firms having failed to navigate key pieces of intellectual property.
You may also be interested in...
Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars
As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.
China And US Added to Amneal-Iconovo Symbicort Alliance
Swedish player Iconovo is in line for larger future royalties through its partnership with Amneal covering a generic version of AstraZeneca’s Symbicort, after the two firms signed a new, expanded agreement.
Sandoz Shakes Up US Albuterol Market With Proventil Deal
Sandoz has struck a US deal to in-license both branded Proventil HFA and an authorized generic version of the albuterol sulfate product from Kindeva Drug Delivery. The deal comes after a busy year for generic versions of albuterol that have transformed the market dynamics for the respiratory treatment.